Obtaining and analyzing plasmasamples from patients with non small cell lung cancer, referred for radiation treatment and/or chemotherapy

Completed

• Conditions: non small cell lung cancer; 10027656

• Registration Number: NL-OMON47175
• Lead Sponsor: MAASTRO clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

• Participant is willing and able to give informed consent for participation in the trial.
• Male or female, aged 18 years or above.
• Diagnosed with non-small cell lung cancer
• Scheduled to receive one of the following two therapeutic strategies:
- Concurrent cisplatin-doublet chemotherapy and radiotherapy (minimal dose of 60 Gy in fractionated non-ablative doses) in patients with stage III NSCLC
- SBRT for stage I NSCLC: 54Gy in 3 fractions, 48 Gy in 4 fractions or 60 Gy in 8 or 5 fractions
• Is able and willing to comply with all trial requirements.

Exclusion Criteria

- Chronic use of corticosteroids, except when used as anti-emetics for chemotherapy or inhalers
- NSAIDs taken until 5 days before radiotherapy or during radiation (low dose Aspirin at a maximum of 160 mg/day, is allowed)
- Active auto-immune diseases
- Immunosuppressive medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Changes of relative protein expression / lipid profile for plasma /<br /><br>plasma-derived exosomes, linked to ICD</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Changes of relative protein expression, linked to Th1 / Th2 subsets<br /><br>- Changes of relative protein expression, linked to vascular damage</p><br>